


## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **DR. AGARWAL'S EYE HOSPITAL LIMITED** ("the Company") for the Quarter ended 30 June 2016 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting AS - 25 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**  
Chartered Accountants  
(Firm's Registration No. 008072S)

  
**Sriraman Parthasarathy**  
Partner  
(Membership No. 206834)

Chennai, 1 August 2016  
PS/RB/2016





**Dr. Agarwal's Eye Hospital Limited**

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greaves Road, Chennai - 600 006

Phone No. 91-44-39916669, Website : www.dragarwal.com, E-mail : investor@dragarwal.com, CIN : L85110TN1994PLC027366

**Statement of Unaudited Financial Results for the Quarter Ended 30 June 2016**

S.NO	Particulars	Quarter Ended			Amount in Rs. Lacs
		30-Jun-16 Unaudited	31-Mar-16 Audited (Refer Note 3)	30-Jun-15 Unaudited	
1	(a) Net Sales/Income from operations	3,836.85	3,480.59	3,578.24	13,466.70
	(b) Other Operating Income	-	51.72	23.86	189.19
	<b>Total Income</b>	<b>3,836.85</b>	<b>3,532.31</b>	<b>3,602.10</b>	<b>13,655.89</b>
2	<b>Expenditure</b>				
	(a) Purchase of Stock-in-trade	477.00	439.00	488.55	1,778.04
	(b) Changes in inventories of stock-in-trade	43.68	60.36	(43.95)	18.96
	(c) Consumables	593.19	381.17	469.26	1,566.26
	(d) Consultancy Charges	496.73	486.44	536.81	1,973.92
	(e) Employee Benefit Expenses	754.84	873.35	661.69	2,926.14
	(f) Depreciation and Amortisation Expense	194.71	262.13	175.75	852.62
	(g) Rent	400.38	314.76	357.06	1,456.96
	(h) Other Expenditure	531.43	530.80	624.20	2,242.18
	(i) Prior Period Items	-	-	290.72	542.43
	<b>Total</b>	<b>3,491.96</b>	<b>3,348.01</b>	<b>3,560.29</b>	<b>13,357.51</b>
3	<b>Profit from Operations before Other Income, Finance cost &amp; Exceptional Items (1-2)</b>	<b>344.89</b>	<b>184.30</b>	<b>41.81</b>	<b>298.38</b>
4	Other Income	3.28	12.05	3.74	27.83
5	Profit from Ordinary activities before Finance Cost & Exceptional Items (3+4)	348.17	196.35	45.55	326.21
6	Finance Cost	86.81	91.35	89.00	374.36
7	<b>Profit / (Loss) from Ordinary activities after Finance cost but before Exceptional Items (5-6)</b>	<b>258.36</b>	<b>105.00</b>	<b>(43.45)</b>	<b>(48.15)</b>
8	Exceptional Items	-	-	-	-
9	<b>Profit / (Loss) from Ordinary Activities before Tax (7+8)</b>	<b>258.36</b>	<b>105.00</b>	<b>(43.45)</b>	<b>(48.15)</b>
10	Tax Expenses	-	-	-	-
	- relating to the current period	85.44	28.18	38.53	135.93
	- relating to the prior years	-	-	(96.12)	(187.75)
11	<b>Net Profit from Ordinary Activities after Tax (9-10)</b>	<b>172.92</b>	<b>76.82</b>	<b>14.14</b>	<b>3.67</b>
12	Extraordinary Items (net of tax expense)	-	-	-	-
13	<b>Net Profit for the period (11-12)</b>	<b>172.92</b>	<b>76.82</b>	<b>14.14</b>	<b>3.67</b>
14	Paid-up equity share capital ( Face value Rs.10/- each)	470.00	470.00	470.00	470.00
15	Reserves excluding Revaluation Reserves (as per balance sheet) of previous accounting year	-	-	-	1,872.11
16	Earnings Per Share (EPS) (of Rs. 10/- each not annualised for the quarters)				
	(a) Basic	3.68	1.63	0.30	0.08
	(b) Diluted	3.68	1.63	0.30	0.08
17	Dividend per share (Face Value of Rs. 10/- each)	-	-	-	-
	- Final dividend on equity shares (in Rs. per share)	-	0.80	-	0.80

**Notes :**

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at the Meeting held on 1 August 2016. The Statutory Auditors of Company have carried out a Limited Review of the above Unaudited Financial Results for the Quarter Ended 30 June 2016.
- The Company has identified the business segment which is "Eye Care related Sales and Services" as its primary segment. The amounts appearing in the results relate to this segment.
- Figures of the quarter ended 31 March 2016 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the relevant financial year.
- Previous period / year figures have been regrouped wherever necessary, to conform with the current period presentation.

Place : Chennai  
Date : 01.08.2016



By the Order of the Board

*(Signature)*

Dr. Amar Agarwal  
Chairman & Managing Director  
DIN NO. 00435684